Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 5/20 | 0.62 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | FLT1 | P17948 | 5/20 | 0.47 |
| ▸ | FLT4 | P35916 | 5/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620924 | 1.00 | VCP (0.62) | VCPSIRT7KDRFLT1FLT4 | |
| SCHEMBL22925918 | 0.85 | VCP (0.44) | VCPSIRT7KDRFLT1FLT4 | |
| SCHEMBL22925496 | 0.84 | TRPV1 (0.47) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL29620900 | 0.84 | KDR (0.45) | VCPSIRT7KDRFLT1FLT4 | |
| SCHEMBL28733673 | 0.84 | KDR (0.45) | VCPSIRT7KDRFLT1FLT4 | |
| SCHEMBL29620967 | 0.84 | TRPV1 (0.47) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL24636886 | 0.83 | VCP (0.53) | VCPSIRT7KDRFLT1FLT4 | |
| SCHEMBL29621095 | 0.83 | VCP (0.53) | VCPSIRT7KDRFLT1FLT4 | |
| SCHEMBL22925978 | 0.83 | FLT1 (0.44) | VCPSIRT7KDRFLT1FLT4 | |
| SCHEMBL29620981 | 0.83 | FLT1 (0.44) | VCPSIRT7KDRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | VCP 595/4885SIRT7 964/4885KDR 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.